Capricor Therapeutics Hits Day Low of $29.41 Amid Price Pressure

Capricor Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable decline today, with its stock price dropping by 8.74%. The stock reached an intraday low of USD 29.41, reflecting a challenging trading session. Despite a strong performance over the past year, where the stock has surged by 138.47%, recent financial metrics indicate a downturn in profitability. The company has reported negative results for the last four consecutive quarters, with a pre-tax profit of USD -24.57 million, marking a significant decline of 40.45%. Additionally, the operating cash flow has reached its lowest point at USD -61.04 million. In terms of market position, Capricor's performance over various time frames shows volatility, with a year-to-date increase of 5.68% compared to the S&P 500's decline of 3.12%. However, the stock's risk profile appears elevated, as it trades at valuations that are considered risky relative to historical averages. The company's return on equity stands at a concerning -97.76%, further highlighting the financial challenges it faces.